Catalent announces cell line sales agreement with CEVEC
13 November 2012 | By Catalent Pharma Solutions
Deal follows study which achieved record yield for human alpha-1 antitrypsin (hAAT) molecule...
List view / Grid view
News
Amgen and Pfizer highlight data to be presented at American College of Rheumatology Meeting
12 November 2012 | By Amgen
Amgen and Pfizer announced that results from several Enbrel® (etanercept) studies...
Abbott announces results of analysis exploring the use of HUMIRA® in simultaneously achieving three key treatment goals for RA
12 November 2012 | By Abbott
Results from a post-hoc analysis...
AstraZeneca announces top-line phase III results from naloxegol pivotal trials in patients with opioid-induced constipation
12 November 2012 | By AstraZeneca
AstraZeneca announced positive top-line results from two Phase III trials...
Boehringer Ingelheim enters strategic collaboration agreement
12 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Molecular Partners have entered into a strategic manufacturing collaboration...
Novartis new two-year data with Certican® shows positive outcomes at 24 months in largest liver transplant trial to date
12 November 2012 | By Novartis
New two-year results...
Abbott announces first long-term patient-reported health outcomes data for investigational use of HUMIRA® in patients with active nr-axSpA
12 November 2012 | By Abbott
The first long-term patient-reported health outcomes data...
Investigational Triple DAA regimen of daclatasvir, asunaprevir and BMS-791325 achieved SVR12 of 94% in treatment-naïve patients with genotype 1 chronic hepatitis C infection in Phase II trial
12 November 2012 | By Bristol-Myers Squibb Company
Phase III development anticipated to begin in 2014...
Merck presents early-stage interim data for MK-3475, an investigational therapy for the treatment of advanced Melanoma
11 November 2012 | By Merck
Merck announced the presentation of early interim results...
Novartis data show ACZ885 delivered rapid and strong symptom relief while reducing frequency of attacks in two periodic fever syndromes
11 November 2012 | By Novartis
New data from two Phase II trials of ACZ885...
Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease
10 November 2012 | By Boehringer Ingelheim
Pivotal Phase III interferon-free study being initiated following positive Phase IIb results...
RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants
9 November 2012 | By GlaxoSmithKline
Results from ongoing Phase III clinical trial announced...
Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval
9 November 2012 | By Novo Nordisk
“The positive vote from the Advisory Committee marks an important step..."
RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa®
8 November 2012 | By Boehringer Ingelheim
Pivotal data from the RELY-ABLE® study have provided additional data...
Novartis future growth prospects secured by industry-leading pipeline, with more than 139 projects with 73 new compounds
8 November 2012 | By Novartis
Update on leading R&D pipeline...
